FHTX

Foghorn Therapeutics Inc.

• Reuters·03/30 21:31

  4D Molecular Therapeutics names CFO Kristian Humer principal accounting officer

• Dow Jones·03/12 15:28

  Foghorn Therapeutics Price Target Maintained With a $10.00/Share by Wedbush

• Benzinga·03/12 15:18

  Wedbush Reiterates Outperform on Foghorn Therapeutics, Maintains $10 Price Target

• TipRanks·03/12 12:17

  Wedbush Reaffirms Their Buy Rating on Foghorn Therapeutics (FHTX)

• TipRanks·03/12 11:39

  Foghorn Therapeutics (FHTX) Receives a Buy from Guggenheim

• TipRanks·03/12 11:36

  Maintaining Buy on Foghorn: Advancing FHD-909, Productive Discovery Engine, and Cash Runway Drive Attractive Risk–Reward Ahead of Key 2026 Catalyst

• TipRanks·03/12 10:50

  Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), RegenXBio (RGNX) and Foghorn Therapeutics (FHTX)

• TipRanks·03/12 10:16

  Buy Rating on Foghorn Therapeutics Driven by Lilly Partnership Catalyst, Advancing Degrader Pipeline, and Strengthened Cash Runway

• TipRanks·03/12 01:29

  Foghorn Advances FHD-909 Trial and Strengthens Financial Position

• Seeking Alpha·03/11 20:38

  Foghorn Therapeutics GAAP EPS of -$1.18 misses by $0.08, revenue of $30.91M misses by $0.31M

• Benzinga·03/11 20:24

  Foghorn Therapeutics Q4 EPS $(0.34) Misses $(0.27) Estimate, Sales $9.247M Miss $9.500M Estimate

• Reuters·03/11 20:21

  Foghorn Therapeutics FY 2025 collaboration revenues rise 37% to USD 30.9 million, net loss narrows 14% to USD 74.3 million

• Dow Jones·03/11 20:16

  *Foghorn Therapeutics FY25 Rev $30.9M >FHTX

• Dow Jones·03/11 20:16

  *Foghorn Therapeutics FY25 Loss/Shr $1.18 >FHTX

• Reuters·03/11 20:09

  FOGHORN THERAPEUTICS PROVIDES FINANCIAL UPDATE FOR 2025 AND 2026 STRATEGIC OUTLOOK